The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Suven has already begun planning a global Phase 3 registrational program for MDD based on the results
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
